Recap of Immuno-oncology Series, Day 70

Over the past 17 days, I immersed myself in one of the most complex, rapidly evolving, and intellectually demanding fields in modern biomedicine: 𝘪𝘮𝘮𝘶𝘯𝘰-𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺. 
 
We started with checkpoint inhibitors 
𝗗𝗮𝘆 𝟱𝟮: https://lnkd.in/edQvsiKH 

We moved into the engineered immune cells: 
𝗗𝗮𝘆 𝟱𝟯: Adoptive Cell Therapy https://lnkd.in/erxEqwYi 
𝗗𝗮𝘆 𝟱𝟰: CAR-T https://lnkd.in/ezKSk_8p 

The world of immune-activating viruses: 
𝗗𝗮𝘆 𝟱𝟵: https://lnkd.in/ejQPuAV6 

Then BiTEs: 
𝗗𝗮𝘆 𝟲𝟬: https://lnkd.in/evY3p9MR 

And we explored innate cell therapies: 
𝗗𝗮𝘆 𝟲𝟮: Macrophage-Based Therapies https://lnkd.in/ewVU7wa7 

We covered: 
𝗗𝗮𝘆 𝟲𝟳: Clinical Trials and https://lnkd.in/ej5g-kFV 

Ended with one of the most fascinating, lesser-known frameworks: 
𝗗𝗮𝘆 𝟲𝟵: Individueller Heilversuch (link) 
 
𝗪𝗵𝗮𝘁 𝗜 𝗟𝗲𝗮𝗿𝗻𝗲𝗱 𝗶𝗻 𝟭𝟳 𝗗𝗮𝘆𝘀 
1. TME and antigen escape are the deal-breakers. 
2. Combination therapy is the future. 
3. Innate and adaptive immunity are deeply intertwined. 
4. Personal lesson: I can clearly connect my current industrial role to the bigger scientific and clinical picture. Had I not reached out to colleagues out of intellectual starvation (and received their kindness ☺️), I might still be lost in the woods of scientific, clinical, and industrial nowhere. 
 
This 70-day project helped me reclaim my curiosity, direction, and identity as a scientist. 
 
𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗔𝘂𝗱𝗶𝗲𝗻𝗰𝗲 
Which immuno-oncology modality do you believe will define the next decade? 
 
Stay tuned for 𝗗𝗮𝘆 𝟳𝟭: 𝗣𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲𝘀 𝗼𝗳 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗖𝗹𝗼𝗻𝗶𝗻𝗴: 𝗔 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄 𝗳𝗼𝗿 𝗠𝗼𝗱𝗲𝗿𝗻 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 
 
#ImmunoOncology #CancerResearch #CellTherapy #CART #BITE #OncolyticViruses #TumorMicroenvironment #NKCells #MacrophageTherapy #PrecisionMedicine #ClinicalTrials hashtag#IMPs #Heilversuch #TranslationalResearch #Biotech #DrugDevelopment #PharmaScience #100DaysofImmunology